

cofinanced by funds from the Health Research Fund of the Carlos III Health Institute (FISPI18/01233).

AUTHORS' CONTRIBUTIONS

All authors have contributed to the design, writing, and critical analysis of the article.

CONFLICTS OF INTEREST

The authors have no conflicts of interest related to this article.

Alejandro Cruz-Utrilla,^{a,b,*} Natalia Gallego,^{c,d,e}
Alba Torrent-Vernetta,^{d,f} Inmaculada Guillén,^g
María Pilar Escribano Subias,^{a,b} and María Jesús del Cerro Marín^h

^aUnidad de Hipertensión Pulmonar, Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain

^bCentro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Spain

^cInstituto de Genética Médica y Molecular (INGEMM), IdiPaz, Hospital Universitario La Paz, Madrid, Spain

^dCentro Nacional de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Spain

^eITHACA, European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability, Bruselas, Belgium

^fSección de Alergología, Neumología Pediátrica y Fibrosis Quística, Vall

d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain

^gServicio de Cardiología Pediátrica, Departamento de Pediatría, Hospital Universitario Virgen del Rocío, Seville, Spain

^hServicio de Cardiología Pediátrica, Departamento de Pediatría, Hospital Universitario Ramón y Cajal, Madrid, Spain

* Corresponding author:

E-mail address: acruzutrilla@gmail.com (A. Cruz-Utrilla).

Available online 17 January 2022

REFERENCES

1. Zijlstra WM, Elmasry O, Peplinkhuizen S, et al. Pulmonary arterial hypertension in children after neonatal arterial switch operation. *Heart*. 2017;103:1244–1249.
2. del Cerro Marín MJ, Sabaté Rotés A, et al. REHIPED Investigators. Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry. *Am J Respir Crit Care Med*. 2014;190:1421–1429.
3. Castaño JAT, Hernández-González I, Gallego N, et al. Customized massive parallel sequencing panel for diagnosis of pulmonary arterial hypertension. *Genes*. 2020;11:1158.
4. Woudstra O, Skoric-Milosavljevic. Post MC, et al. Common genetic variants improve risk stratification after atrial switch operation for transposition of the great arteries. *Eur Heart J*. 2021. <http://doi.org/10.1093/eurheartj/ehab724.1855>.

<https://doi.org/10.1016/j.rec.2021.12.006>
1885-5857/

© 2021 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

An unusual case of *Brucella* endocarditis involving a prosthetic pulmonary valve



Un caso inusual de endocarditis por *Brucella* que afecta a una válvula pulmonar protésica

To the Editor,

Brucella is one of the most important zoonotic infections worldwide caused by the intracellular Gram-negative bacteria *Brucella*, which is transmitted to humans either through contaminated food or via direct contact with infected animals.¹ *Brucella* endocarditis (BE) is one of the most feared complication of brucellosis today since it can be life-threatening.

Brucella is endemic in animals and humans within the Middle East region, including Lebanon. Of note, the fifth largest world outbreak of *Brucella* occurred in Lebanon beginning in 2017 with a total of 1180 cases.² According to the World Health Organization Eastern Mediterranean Regional Office (EMRO), the annual incidence of brucellosis in Lebanon was between 3.5 and 9 cases per 100 000 inhabitants from 1997 to October 2009.³ Due to its endemicity, it is common in clinical practice in Lebanon to include brucellosis in the differential diagnosis when working up a patient with fever of unknown origin.

There are only a few case reports in the literature about BE due to infrequent recognition of the disease. The organism appears to have a predilection for invading damaged endocardial tissue and tends to cause aortic and mitral valve endocarditis.⁴ While some case reports describe BE involving the mitral and aortic valves, cases of BE involving the pulmonary valve are exceedingly rare in the literature. We herein present such a case.

A 41-year-old woman presented to the clinic for a 1-month history of intermittent fever reaching 39 °C and occasional cough.

She also complained of fatigue and persistent nausea during the last month. Her past medical history was significant for Tetralogy of Fallot, for which she underwent 2 surgical corrections at 3 and 9 years of age. She also had pulmonary valve replacement and patch repair of her ventricular septal defect 10 years previously. She denied any exposure to pets or intravenous drug use. At her initial presentation, all her vital signs, including temperature, were within the reference range. Physical examination did not yield any significant findings except a systolic ejection murmur on the left sternal border. Initial blood tests revealed mild leukopenia with a white blood cell count (WBC) of 3300/cu.mm (reference range 4000–11 000/cu.mm) and mildly elevated transaminase enzymes (serum glutamic-oxaloacetic transaminase of 62 units/L and serum glutamic pyruvic transaminase of 57 units/L). The patient also had elevated lactate dehydrogenase of 288 units/L. C-reactive protein and erythrocyte sedimentation rate were elevated at values of 29.6 mg/L and 50 mm/h, respectively. *Brucella* serology was ordered and both direct and indirect titers were positive at 1:320. She was therefore treated with doxycycline and trimethoprim-sulfamethoxazole for 6 weeks and improved significantly. However, 2 months later, her symptoms recurred. Blood culture was positive for *Brucella* and antibody titers were unchanged. Transthoracic echocardiography showed severe right ventricular dilation and 2 masses consistent with vegetations on the pulmonary valve, the larger of the 2 measuring 12 mm in length. Transesophageal echocardiography showed moderate regurgitation of the pulmonary valve prosthesis with accompanying vegetations and no abscess, in addition to the presence of a hypermobile oscillating mass in the pulmonary artery with no evidence of abscess formation (figure 1). All the other valves were normal.

Medical treatment was initiated and the patient was started on streptomycin 1 g intramuscularly daily, doxycycline 100 mg orally




Figure 1. Transesophageal echocardiography showing moderate regurgitation of the pulmonary valve prosthesis with accompanying vegetations (blue arrow).

twice daily, and rifampin 600 mg orally daily. Six weeks after treatment, the patient showed mild symptom improvement. The rifampin dose was increased to 900 mg daily and, 2 months later, she showed with almost complete symptom resolution with only mild residual fatigue. The patient consented for the publication of the case.

The cases of BE described in the literature involve mainly the aortic or mitral valves, such as the case of brucellosis-related endocarditis and spondylitis due to *Brucella melitensis biovar* that was reported by Whuan Zhuan et al.⁴

Only 2 cases of *Brucella* endocarditis of the pulmonary valve have been reported in the literature (table 1). The first was a 14-year-old patient who was treated for transposition of the great vessels and who had pulmonary valve stenosis with mitral insufficiency and was then diagnosed with BE involving both the pulmonic and mitral valves⁵. Kasinadhuni et al.⁶ also described a patient with BE involving a structurally normal pulmonary valve and without any predisposing factors such as intravenous drug abuse. As in our case, both patients were managed with medical treatment only. However, our case is unique in that it involves a prosthetic rather than a native pulmonary valve. The therapeutic regimen adopted for our patient was based on a World Health Organization recommendation that includes doxycycline plus an aminoglycoside alongside trimethoprim-sulfamethoxazole or rifampin for at least 8 weeks.

FUNDING

None.

AUTHORS' CONTRIBUTIONS

All authors contributed equally.

CONFLICTS OF INTEREST

None.

Rami George Maalouf,^a Darine Daher,^b Abdallah Rebeiz,^c and Zeina Kanafani^{d,*}

^aDepartment of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

^bFaculty of Medicine, American University of Beirut, Beirut, Lebanon

^cDivision of Cardiology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

^dDivision of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

* Corresponding author:

E-mail address: zk10@aub.edu.lb (Z. Kanafani).

Available online 18 December 2021

REFERENCES

1. Koruk ST, Erdem H, Koruk I, et al. Management of *Brucella* endocarditis: results of the Gulhane study. *Int J Antimicrob Agents*. 2012;40:145–150.

2. Sabra A, Masry B, Shaib H. A Review of Brucellosis: A Recent Major Outbreak in Lebanon. *JESPH*. 2021;5:56–76.
3. Al-Shaar L, Chaaya M, Ghosn N, Mahfoud Z. Brucellosis outbreak in Chouf district of Lebanon in 2009: a case-control study. *East Mediterr Health J*. 2014;20:250–256.
4. Zhang H, Xie S, Wang Y. A case report of endocarditis and spondylitis caused by *Brucella melitensis* biovar 3. *BMC Infect Dis*. 2021;21:460.
5. Urruticoeche PG, Luciano JL, Marcuschamer J, Reyes P. Infectious *Brucella* endocarditis in a case of corrected transposition of the great arteries. *Arch Inst Cardiol Mex*. 1988;58:57–59.
6. Kasinadhuni GN, Kumar MH, Sharma AK, Vijayvergua R. *Brucella* endocarditis of pulmonary valve: A rare presentation. *BMJ Case Rep*. 2020. <http://doi.org/10.1136/bcr-2019-229269>.
<https://doi.org/10.1016/j.rec.2021.11.008>
1885-5857/
© 2021 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Cardiología.